Supporting evidence from optical coherence tomography for shortening dual antiplatelet therapy after drug-eluting stents implantation

References

• Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193–202.
   PubMed Web of Science ®Google Scholar
• Finn AV, Joner M, Nakazawa G, et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation. 2007;115:2435–2441.
   PubMed Web of Science ®Google Scholar
• Levine GN, Bates ER, Bittl JA, et al. ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation. 2016;134:e123–155.
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39:213–260.
   PubMed Web of Science ®Google Scholar
• Costa F, Van Klaveren D, Feres F, et al. Dual antiplatelet therapy duration based on ischemic and bleeding risks after coronary stenting. J Am Coll Cardiol. 2019;73:741–754.
   PubMed Web of Science ®Google Scholar
• Palmerini T, Benedetto U, Bacchi-Reggiani L, et al. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet. 2015;385:2371–2382.
   PubMed Web of Science ®Google Scholar
• Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371:2155–2166.
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Patialiakas A, Thury A, et al. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J Am Coll Cardiol. 2015;65:805–815.
   PubMed Web of Science ®Google Scholar
• Naber CK, Urban P, Ong PJ, et al. Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a Leaders Free ACS sub-study. Eur Heart J. 2017;38:961–969.
   PubMedGoogle Scholar
• Morice MC, Talwar S, Gaemperli O, et al. Drug-coated versus bare-metal stents for elderly patients: A predefined sub-study of the LEADERS FREE trial. Int J Cardiol. 2017;243:110–115.
   PubMed Web of Science ®Google Scholar
• Lipiecki J, Brunel P, Morice MC, et al. Biolimus A9 polymer-free coated stents in high bleeding risk patients undergoing complex PCI: evidence from the LEADERS FREE randomised clinical trial. EuroIntervention. 2018;14:e418–425.
   PubMed Web of Science ®Google Scholar
• Watanabe H, Domei T, Morimoto T, et al. Effect of 1-month dual antiplatelet therapy followed by Clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. JAMA. 2019;321:2414–2427.
   PubMed Web of Science ®Google Scholar
• Kedhi E, Latib A, Abizaid A, et al. Rationale and design of the Onyx ONE global randomized trial: A randomized controlled trial of high-bleeding risk patients after stent placement with 1month of dual antiplatelet therapy. Am Heart J. 2019;214:134–141.
   PubMed Web of Science ®Google Scholar
• Frigoli E, Smits P, Vranckx P, et al. Design and rationale of the management of high bleeding risk patients post bioresorbable polymer coated stent implantation with an abbreviated versus standard DAPT regimen (MASTER DAPT) study. Am Heart J. 2019;209:97–105.
   PubMed Web of Science ®Google Scholar
• Filipovic-Pierucci A, Durand-Zaleski I, Butel T, et al. Polymer-free drug-coated coronary stents are cost-effective in patients at high bleeding risk: economic evaluation of the LEADERS FREE trial. EuroIntervention. 2018;13:1688–1695.
   PubMed Web of Science ®Google Scholar
• Otsuka F, Vorpahl M, Nakano M, et al. Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans. Circulation. 2014;129:211–223.
   PubMed Web of Science ®Google Scholar
• Raber L, Mintz GS, Koskinas KC, et al. Clinical use of intracoronary imaging. part 1: guidance and optimization of coronary interventions. An expert consensus document of the european association of percutaneous cardiovascular interventions. Eur Heart J. 2018;39:3281–3300.
   PubMed Web of Science ®Google Scholar
• Murata A, Wallace-Bradley D, Tellez A, et al. Accuracy of optical coherence tomography in the evaluation of neointimal coverage after stent implantation. JACC Cardiovasc Imaging. 2010;3:76–84.
   PubMed Web of Science ®Google Scholar
• Raber L, Zanchin T, Baumgartner S, et al. Differential healing response attributed to culprit lesions of patients with acute coronary syndromes and stable coronary artery after implantation of drug-eluting stents: an optical coherence tomography study. Int J Cardiol. 2014;173:259–267.
   PubMed Web of Science ®Google Scholar
• Goryo Y, Kume T, Ueda T, et al. Vascular healing response after everolimus-eluting stent implantation in acute coronary syndrome culprit lesions: comparison with implantation in stable angina pectoris. Acta Cardiol Sin. 2018;34:124–129.
   PubMed Web of Science ®Google Scholar
• Sato N, Minami Y, Shimohama T, et al. Vascular response and intrastent thrombus in the early phase after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: an observational, single-center study. Health Sci Rep. 2019;2:e105.
   PubMedGoogle Scholar
• Yano H, Horinaka S, Watahik M, et al. Comparison of the vessel healing process after everolimus-eluting stent and bare metal stent implantations in patients with ST-elevation myocardial infarction. Heart Vessels. 2019;34:572–582.
   PubMed Web of Science ®Google Scholar
• Joner M, Nakazawa G, Finn AV, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol. 2008;52:333–342.
   PubMed Web of Science ®Google Scholar
• Park KW, Kang SH, Velders MA, et al. Safety and efficacy of everolimus- versus sirolimus-eluting stents: a systematic review and meta-analysis of 11 randomized trials. Am Heart J. 2013;165:241–250 e4.
   PubMed Web of Science ®Google Scholar
• Kim BK, Kim JS, Park J, et al. Comparison of optical coherence tomographic assessment between first- and second-generation drug-eluting stents. Yonsei Med J. 2012;53:524–529.
   PubMed Web of Science ®Google Scholar
• Prati F, Stazi F, Dutary J, et al. Detection of very early stent healing after primary angioplasty: an optical coherence tomographic observational study of chromium cobaltum and first-generation drug-eluting stents. The DETECTIVE study. Heart. 2011;97:1841–1846.
   PubMed Web of Science ®Google Scholar
• La Manna A, Prati F, Capodanno D, et al. Head-to-head comparison of early vessel healing by optical coherence tomography after implantation of different stents in the same patient. J Cardiovasc Med. 2011;12:328–333.
   Google Scholar
• Oka N, Fujii K, Kadohira T, et al. Assessment of strut coverage of everolimus-eluting platinum chromium stent 2 weeks after implantation by optical coherence tomography. Heart Vessels. 2019;34:1258–1265.
   PubMed Web of Science ®Google Scholar
• Nishinari M, Shimohama T, Tojo T, et al. Two-week interval optical coherence tomography: imaging evidence on neointimal coverage completion after implantation of the Endeavor zotarolimus-eluting stent. Catheter Cardiovasc Interv. 2013;82:E871–878.
   PubMed Web of Science ®Google Scholar
• Takahara M, Kitahara H, Nishi T, et al. Very early tissue coverage after drug-eluting stent implantation: an optical coherence tomography study. Int J Cardiovasc Imaging. 2017;33:25–30.
   PubMed Web of Science ®Google Scholar
• Laine M, Dabry T, Combaret N, et al. OCT Analysis of very early strut coverage of the synergy stent in non-ST segment elevation acute coronary syndrome patients. J Invasive Cardiol. 2019;31:10–14.
   PubMed Web of Science ®Google Scholar
• Asano T, Jin Q, Katagiri Y, et al. A randomised comparison of healing response between the BuMA Supreme stent and the XIENCE stent at one-month and two-month follow-up: PIONEER-II OCT randomised controlled trial. EuroIntervention. 2018;14:e1306–1315.
   PubMed Web of Science ®Google Scholar
• Shinke T, Itoh T, Ishida M, et al. Early and mid-term vascular responses to optical coherence tomography-guided everolimus-eluting stent implantation in stable coronary artery disease. Can J Cardiol. 2019;35:1513–1522.
   PubMed Web of Science ®Google Scholar
• Jaguszewski M, Aloysius R, Wang W, et al. The REMEDEE-OCT Study: an evaluation of the bioengineered COMBO dual-therapy CD34 antibody-covered sirolimus-eluting coronary stent compared with a cobalt-chromium everolimus-eluting stent in patients with acute coronary syndromes: insights from optical coherence tomography imaging analysis. JACC Cardiovasc Interv. 2017;10:489–499.
   PubMed Web of Science ®Google Scholar
• Morino Y, Terashita D, Otake H, et al. Early vascular responses to everolimus-eluting cobalt–chromium stent in the culprit lesions of st-elevation myocardial infarction: results from a multicenter prospective optical coherence tomography study (MECHANISM-AMI 2-week follow-up study). Cardiovasc Interv Ther. 2018;34:14–24.
   PubMed Web of Science ®Google Scholar
• Hashikata T, Tojo T, Namba S, et al. Neointimal coverage of zotarolimus-eluting stent at 1, 2, and 3 months’ follow-up: an optical coherence tomography study. Heart Vessels. 2016;31:206–211.
   PubMed Web of Science ®Google Scholar
• Secco GG, Mattesini A, Fattori R, et al. Time-related changes in neointimal tissue coverage of a novel sirolimus eluting stent: serial observations with optical coherence tomography. Cardiovasc Revasc Med. 2016;17:38–43.
   PubMed Web of Science ®Google Scholar
• Karjalainen PP, Varho V, Nammas W, et al. Early neointimal coverage and vasodilator response following biodegradable polymer sirolimus-eluting vs. durable polymer zotarolimus-eluting stents in patients with acute coronary syndrome -HATTRICK-OCT trial. Circ J. 2015;79:360–367.
   PubMed Web of Science ®Google Scholar
• Varho V, Kiviniemi TO, Nammas W, et al. Early vascular healing after titanium-nitride-oxide-coated stent versus platinum-chromium everolimus-eluting stent implantation in patients with acute coronary syndrome. Int J Cardiovasc Imaging. 2016;32:1031–1039.
   PubMed Web of Science ®Google Scholar
• Chevalier B, Smits PC, Carrie D, et al. Serial assessment of strut coverage of biodegradable polymer drug-eluting stent at 1, 2, and 3 months after stent implantation by optical frequency domain imaging: the DISCOVERY 1TO3 study (Evaluation with OFDI of strut coverage of Terumo new drug eluting stent with biodegradable polymer at 1, 2, and 3 months). Circ Cardiovasc Interv. 2017;10:e004801.
   PubMed Web of Science ®Google Scholar
• Izumi D, Miyahara M, Fujimoto N, et al. Optical coherence tomography analysis of the stent strut and prediction of resolved strut malapposition at 3 months after 2nd-generation drug-eluting stent implantation. Heart Vessels. 2016;31:1247–1256..
   PubMed Web of Science ®Google Scholar
• Prati F, Romagnoli E, Valgimigli M, et al. Randomized comparison between 3-month Cre8 DES vs. 1-month Vision/Multilink8 BMS neointimal coverage assessed by OCT evaluation: the DEMONSTRATE study. Int J Cardiol. 2014;176:904–909.
   PubMed Web of Science ®Google Scholar
• de la Torre Hernandez JM, Tejedor P, Camarero TG, et al. Early healing assessment with optical coherence tomography of everolimus-eluting stents with bioabsorbable polymer (synergy) at 3 and 6 months after implantation. Catheter Cardiovasc Interv. 2016;88:E67–73.
   PubMed Web of Science ®Google Scholar
• Kim JS, Jang IK, Fan C, et al. Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography: the ENDEAVOR OCT trial. JACC Cardiovasc Interv. 2009;2:1240–1247.
   PubMed Web of Science ®Google Scholar
• Kim BK, Hong MK, Shin DH, et al. Optical coherence tomography analysis of strut coverage in biolimus- and sirolimus-eluting stents: 3-month and 12-month serial follow-up. Int J Cardiol. 2013;168:4617–4623.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Lee H, Cho JM, et al. Comparison of zotarolimus-eluting stent and everolimus-eluting stent for vascular healing response: serial 3-month and 12-month optical coherence tomography study. Coron Artery Dis. 2013;24:431–439.
   PubMed Web of Science ®Google Scholar
• Lee SWL, Tam FCC, Lam SCC, et al. The OCT-ORION Study. A randomized optical coherence tomography study comparing resolute integrity to biomatrix drug-eluting stent on the degree of early stent healing and late lumen loss. Circ Cardiovasc Interv. 2018;11:e006034.
   PubMed Web of Science ®Google Scholar
• Qian J, Zhang YJ, Xu B, et al. Optical coherence tomography assessment of a PLGA-polymer with electro-grafting base layer versus a PLA-polymer sirolimus-eluting stent at three-month follow-up: the BuMAOCT randomised trial. EuroIntervention. 2014;10:806–814.
   PubMed Web of Science ®Google Scholar
• Puri R, Otaegui I, Sabaté M, et al. Three- and 6-month optical coherence tomographic surveillance following percutaneous coronary intervention with the Angiolite® drug-eluting stent: the ANCHOR study. Catheter Cardiovasc Interv. 2018;91:435–443.
   PubMed Web of Science ®Google Scholar
• Won H, Shin DH, Kim BK, et al. Optical coherence tomography derived cut-off value of uncovered stent struts to predict adverse clinical outcomes after drug-eluting stent implantation. Int J Cardiovasc Imaging. 2013;29:1255–1263.
   PubMed Web of Science ®Google Scholar
• Lee SY, Kim JS, Yoon HJ, et al. Early strut coverage in patients receiving drug-eluting stents and its implications for dual antiplatelet therapy: a randomized trial. JACC Cardiovasc Imaging. 2018;11:1810–1819.
   PubMed Web of Science ®Google Scholar
• Kakizaki R, Minami Y, Hashikata T, et al. Impact of underlying plaque type on strut coverage in the early phase after drug-eluting stent implantation. Coron Artery Dis. 2018;29:624–631.
   PubMed Web of Science ®Google Scholar
• Tijssen RYG, Kraak RP, Lu H, et al. Evaluation of the MiStent sustained sirolimus eluting biodegradable polymer coated stent for the treatment of coronary artery disease: does uniform sustained abluminal drug release result in earlier strut coverage and better safety profile? Expert Rev Med Devices. 2017;14:325–334.
   PubMed Web of Science ®Google Scholar